Types of Heart Failure

The major types of heart failure are:

Because the two ventricles of the heart represent two separate pumping systems, it is possible for one to fail by itself for a short period. Most heart failure begins with failure of the left ventricle and progresses to failure of both ventricles. Typical causes of left-sided heart (ventricular) failure include hypertension, coronary artery disease, and valvular disease involving the mitral or aortic valve. Decreased tissue perfusion from poor cardiac output and pulmonary congestion from increased pressure in the pulmonary vessels indicate left ventricular failure (LVF).

Left-sided heart failure was formerly referred to as congestive heart failure (CHF); however, not all cases of LVF involve fluid accumulation. In the clinical setting, though, the term CHF is still commonly used. Left-sided failure may be acute or chronic and mild to severe. It can be further divided into two subtypes: systolic heart failure and diastolic heart failure.

Systolic heart failure (systolic ventricular dysfunction) results when the heart cannot contract forcefully enough during systole to eject adequate amounts of blood into the circulation. Preload increases with decreased contractility, and afterload increases as a result of increased peripheral resistance (e.g., hypertension) (McCance et al., 2010). The ejection fraction (the percentage of blood ejected from the heart during systole) drops from a normal of 50% to 70% to below 40% with ventricular dilation. As it decreases, tissue perfusion diminishes and blood accumulates in the pulmonary vessels. Manifestations of systolic dysfunction may include symptoms of inadequate tissue perfusion or pulmonary and systemic congestion. Systolic heart failure is often called “forward failure” because cardiac output is decreased and fluid backs up into the pulmonary system. Because these patients are at high risk for sudden cardiac death, patients with an ejection fraction of less than 30% are considered candidates for an implantable cardioverter/defibrillator (ICD; also known as an internal cardioverter/defibrillator) (see Chapter 36).

In contrast, diastolic heart failure (heart failure with preserved left ventricular function) occurs when the left ventricle cannot relax adequately during diastole. Inadequate relaxation or “stiffening” prevents the ventricle from filling with sufficient blood to ensure an adequate cardiac output. Although ejection fraction is more than 40%, the ventricle becomes less compliant over time because more pressure is needed to move the same amount of volume as compared with a healthy heart. Diastolic failure represents about 20% to 40% of all heart failure, primarily in older adults and in women who have chronic hypertension and undetected coronary artery disease. Clinical manifestations and management of diastolic failure are similar to those of systolic dysfunction (McCance et al., 2010).

Right-sided heart (ventricular) failure may be caused by left ventricular failure, right ventricular myocardial infarction (MI), or pulmonary hypertension. In this type of heart failure (HF), the right ventricle cannot empty completely. Increased volume and pressure develop in the venous system, and peripheral edema results.

High-output heart failure can occur when cardiac output remains normal or above normal, unlike left- and right-sided heart failure, which are typically low-output states. High-output failure is caused by increased metabolic needs or hyperkinetic conditions, such as septicemia, high fever, anemia, and hyperthyroidism. This type of heart failure is not as common as other types.

Classification and Staging of Heart Failure

The American College of Cardiology (ACC) and American Heart Association (AHA) have developed evidence-based guidelines for staging and managing heart failure as a chronic, progressive disease. These guidelines do not replace the New York Heart Association (NYHA) functional classification system, which is used to describe symptoms a patient may exhibit (see Table 35-2 in Chapter 35).

The ACC/AHA staging system when compared with the NYHA system categorizes patients as:

Another method for staging HF is the Killip classification system, which is based on the heart’s hemodynamic ability. Table 40-3 in Chapter 40 outlines this system.

Compensatory Mechanisms

When cardiac output is insufficient to meet the demands of the body, compensatory mechanisms work to improve cardiac output (Fig. 37-1). Although these mechanisms may initially increase cardiac output, they eventually have a damaging effect on pump function. Major compensatory mechanisms include:

FIG. 37-1 Left-sided heart failure from elevated systemic vascular resistance. Left heart failure leads to right heart failure. Systemic vascular resistance and preload are exacerbated by renal and adrenal mechanisms. ADH, Antidiuretic hormone; LA, left atrial; LV, left ventricular; LVEDP, left ventricular end-diastolic pressure; RV, right ventricular.

Etiology

Heart failure (HF) is caused by systemic hypertension in most cases. About a third of patients experiencing myocardial infarction (MI, “heart attack”) also develop HF. The next most common cause is structural heart changes, such as valvular dysfunction, particularly pulmonic or aortic stenosis, which leads to pressure or volume overload on the heart. Common direct causes and risk factors for HF are listed in Table 37-1.

TABLE 37-1 COMMON CAUSES AND RISK FACTORS FOR HEART FAILURE

Right-sided HF in the absence of left-sided HF is usually the result of pulmonary problems such as chronic obstructive pulmonary disease (COPD) or pulmonary hypertension. Acute respiratory distress syndrome (ARDS) may also cause right-sided HF. These problems are discussed elsewhere in the cardiac unit.

Incidence/Prevalence

Over five million people in the United States have HF, causing about 875,000 hospitalizations each year. HF is the most common reason for hospital admission for people over 65 years of age. African Americans are affected more often than Euro-Americans, probably because they have more risk factors that can lead to HF. The disease is a major cause of disability and death after MI, often due to nonadherence to the treatment plan and recommended lifestyle changes.

History

When obtaining a history, keep in mind the many conditions that can lead to HF. Carefully question the patient about his or her medical history, including hypertension, angina (cardiac pain), MI, rheumatic heart disease, valvular disorders, endocarditis, and pericarditis. Ask about the patient’s perception of his or her activity tolerance, breathing pattern, sleeping pattern, urinary pattern, and fluid volume status, as well as his or her knowledge about HF.

Physical Assessment/Clinical Manifestations

Manifestations of HF depend on the type of failure, the ventricle involved, and the underlying cause. Impaired tissue perfusion, pulmonary congestion, and edema are associated with left ventricular failure (Chart 37-1). Conversely, systemic venous congestion and peripheral edema are associated with right ventricular failure (Chart 37-2).

Left-Sided Heart Failure

Left ventricular failure is associated with decreased cardiac output and elevated pulmonary venous pressure. It may appear clinically as:

Decreased blood flow to the major body organs can cause dysfunction, especially renal failure. Nocturia may occur when the patient is at rest.

The pulse may be tachycardic, or it may alternate in strength (pulsus alternans). Take the apical pulse for a full minute, noting any irregularity in heart rhythm. An irregular heart rhythm resulting from premature atrial contractions (PACs), premature ventricular contractions (PVCs), or atrial fibrillation (AF) is common in HF (see Chapter 36). The sudden development of an irregular rhythm may further compromise CO. Carefully monitor the patient’s respiratory rate, rhythm, and character, as well as oxygen saturation. The respiratory rate typically exceeds 20 breaths/min.

Assess whether the patient is oriented to person, place, and time. A short mental status examination may be used if there are concerns about orientation. Objective data are important because in daily conversation many people are skillful at covering up memory losses. Older adults are frequently disoriented or confused when the heart fails due to brain hypoxia (decreased oxygen).

Increased heart size is common with a displacement of the apical impulse to the left. A third heart sound, S₃ gallop, is an early diastolic filling sound indicating an increase in left ventricular pressure. This sound is often the first sign of HF. A fourth heart sound (S₄) also can occur; it is not a sign of failure but is a reflection of decreased ventricular compliance.

Auscultate for crackles and wheezes of the lungs. Late inspiratory crackles and fine profuse crackles that repeat themselves from breath to breath and do not diminish with coughing indicate HF. Crackles are produced by intra-alveolar fluid and are often noted first in the bases of the lungs and spread upward as the condition worsens. Wheezes indicate a narrowing of the bronchial lumen caused by engorged pulmonary vessels. Identify the precise location of crackles and wheezes and whether the wheezes are heard on inspiration, expiration, or both.

Right-Sided Heart Failure

Right ventricular failure is associated with increased systemic venous pressures and congestion. On inspection, assess the neck veins for distention and measure abdominal girth. Hepatomegaly (liver engorgement), hepatojugular reflux, and ascites may also be assessed. Abdominal fluid can reach volumes of more than 10 liters.

Assess for dependent edema. In ambulatory patients, edema commonly presents in the ankles and legs. When patients are restricted to bedrest, the sacrum is dependent and fluid accumulates there.

Planning: Expected Outcomes

The expected outcome is that the patient will have an optimal spontaneous breathing pattern that increases oxygenation and maintains a serum carbon dioxide level that is within normal limits.

Interventions

The purpose of collaborative care is to help promote oxygenation and gas exchange. Ventilation assistance may be needed because the oxygen content of the blood is often decreased in patients who have pulmonary congestion. Monitor or have assistive personnel monitor the patient’s respiratory rate, rhythm, and quality every 1 to 4 hours. Auscultate breath sounds every 4 to 8 hours.

Planning: Expected Outcomes

The expected outcome is that the patient will have increased cardiac output by improving stroke volume (SV) (determined by preload, afterload, and contractility) and heart rate (HR).

Interventions

Collaborative care begins with nonsurgical interventions, but the patient may need surgery if these are not successful in meeting optimal outcomes.

Nonsurgical Management

Nonsurgical management relies primarily on a variety of drugs (Table 37-3). If drug therapy is ineffective, other nonsurgical options are available.

TABLE 37-3 COMMONLY USED DRUG CLASSIFICATIONS FOR PATIENTS WITH SYSTOLIC HEART FAILURE

Angiotensin-converting enzyme (ACE) inhibitors or angiotensin-receptor blockers (ARBs) Diuretics: • High-ceiling • Potassium-sparing Human B-type natriuretic peptides Nitrates Inotropics: • Beta-adrenergic agonists • Phosphodiesterase inhibitors • Calcium sensitizers • Digoxin (Lanoxin) Beta-adrenergic blockers

Drugs to improve stroke volume include those that reduce afterload, reduce preload, and improve cardiac muscle contractility. A major role of the nurse is to give medications as prescribed, monitor for their therapeutic and adverse effects, and teach the patient and family about drug therapy. A variety of classes of drugs that reduce afterload and preload are used to manage heart failure (see Table 37-3).

Drugs That Reduce Afterload

By relaxing the arterioles, arterial vasodilators can reduce the resistance to left ventricular ejection (afterload) and improve CO. These drugs do not cause excessive vasodilation but reverse some of the inappropriate or excessive vasoconstriction common in HF.

Angiotensin-Converting Enzyme Inhibitors (ACEIs) and Angiotensin-Receptor Blockers (ARBs)

Patients with even mild heart failure (HF) resulting from left ventricular dysfunction are given a trial of ACE inhibitors or ARBs. Both ACE inhibitors (e.g., enalapril [Vasotec] and fosinopril [Monopril]) and ARBs (e.g., valsartan [Diovan], irbesartan [Avapro], and losartan [Cozaar]) improve function and quality of life for patients with HF. ACE inhibitors are the first-line drug of choice, but some health care providers prefer to start the patient on an ARB because ACE inhibitors can cause a nagging, dry cough. For patients with acute HF, the health care provider may prescribe an IV-push ACE inhibitor such as Vasotec IV.

The ACE inhibitors and ARBs suppress the renin-angiotensin system (RAS), which is activated in response to decreased renal blood flow. ACE inhibitors prevent conversion of angiotensin I to angiotensin II, resulting in arterial dilation and increased stroke volume. ARBs block the effect of angiotensin II receptors and thus decrease arterial resistance and arterial dilation. In addition, these drugs block aldosterone, which prevents sodium and water retention, thus decreasing fluid overload. Both ACEIs and ARBs work more effectively for Euro-Americans than for African-American populations. Volume-depleted patients should receive a low starting dose, or the fluid volume should be restored before beginning the prescribed drug. Monitor for hyperkalemia, a potential adverse drug effect in patients who have renal dysfunction.

 Nursing Safety Priority

Drug Alert

ACEIs and ARBs are started slowly and cautiously. The first dose may be associated with a rapid drop in blood pressure (BP). Patients at risk for hypotension usually have an initial systolic BP less than 100 mm Hg, are older than 75 years, have a serum sodium level less than 135 mEq/L, or are volume depleted. Monitor BP every hour for several hours after the initial dose and each time the dose is increased. Immediately report to the health care provider and document a systolic blood pressure of less than 90 mm Hg (or designated protocol level). If this problem occurs, place the patient flat to increase cerebral perfusion.

Assess for orthostatic hypotension, acute confusion, poor peripheral perfusion, and reduced urine output in patients with low systolic blood pressure. Monitor serum potassium and creatinine levels to determine renal dysfunction. Additional nursing implications for selected ACE inhibitor/ARB drugs are described in Chapter 38 on p. 783 in the Drug Therapy section.

Human B-type Natriuretic Peptides

Human B-type natriuretic peptides (hBNPs) such as nesiritide (Natrecor) are often used to treat acute HF. Endogenous BNP is released in response to decreased CO and causes natriuresis, or loss of sodium in the renal tubules, as well as vasodilation. Natrecor lowers pulmonary capillary wedge pressure (PCWP) and improves renal glomerular filtration. It is given as an IV bolus over 60 seconds followed with a continuous infusion for up to 48 hours.

 Nursing Safety Priority

Drug Alert

When giving Natrecor, monitor BP and pulse carefully because significant decreases in BP may occur. Although the patient’s systolic BP may be between 90 and 100 mm Hg, he or she is usually asymptomatic. Give Natrecor through a separate infusion line because it is incompatible with heparin and most other parenteral medications. Expect an increase in the serum BNP after drug administration.

Interventions That Reduce Preload

Ventricular fibers contract less forcefully when they are overstretched, such as in a failing heart. Interventions aimed at reducing preload attempt to decrease volume and pressure in the left ventricle, increasing ventricular muscle stretch and contraction. Preload reduction is appropriate for HF accompanied by congestion with total body sodium and water overload.

Nutrition Therapy

In HF, nutrition therapy is aimed at reducing sodium and water retention to decrease the workload of the heart. The health care provider may restrict sodium intake in an attempt to decrease fluid retention. Many patients need to omit table salt (no added salt) from their diet, thus reducing sodium intake to about 3 g daily.

If salt intake must be reduced further, the patient may need to eliminate all salt in cooking and high-sodium foods (e.g., ham, bacon, pickles), thus reducing sodium intake to 2 g daily. If needed, collaborate with the dietitian to help the patient select foods that meet such a restricted therapeutic diet.

Few patients are placed on severe fluid restrictions. However, patients with excessive aldosterone secretion may experience thirst and drink 3 to 5 liters of fluid each day. As a result, their fluid intake may be limited to a more normal 2 liters daily. Supervise unlicensed assistive personnel (UAP) to ensure that they limit the prescribed intake and accurately record intake and output.

Weigh the patient daily, or delegate this activity to UAP and supervise that it is done. Keep in mind that 1 kg of weight gain or loss equals 1 liter of retained or lost fluid. The same scale should be used every morning before breakfast for the most accurate assessment of weight. Monitor for an expected decrease in weight because excess fluid is excreted from the body.

Drug Therapy

Common drugs prescribed to reduce preload are diuretics and venous vasodilators. Morphine sulfate is also given for patients in acute heart failure (HF) to reduce anxiety, decrease preload and afterload, slow respirations, and reduce the pain associated with a myocardial infarction (MI).

The health care provider adds diuretics to the regimen when diet and fluid restrictions have not been effective in managing the symptoms of HF. Diuretics are the first-line drug of choice in older adults with HF and fluid overload (Joseph et al., 2009). These drugs enhance the renal excretion of sodium and water by reducing circulating blood volume, decreasing preload, and reducing systemic and pulmonary congestion.

The type and dosage of diuretic prescribed depend on the severity of HF and renal function. High-ceiling (loop) diuretics, such as furosemide (Lasix, Furoside , Novosemide ), torsemide (Demadex), and bumetanide (Bumex), are most effective for treating fluid volume overload.

Considerations for Older Adults

Loop diuretics continue to work even after excess fluid is removed. As a result, some patients, especially older adults, can become dehydrated. Observe for manifestations of dehydration in the older adult, especially acute confusion, decreased urinary output, and dizziness. Provide evidence-based interventions to reduce the risk of falls, as discussed in Chapter 3.

For those patients with acute HF, Lasix or Bumex can be administered by IV push (IVP). Lasix can be given in doses of 20 to 40 mg IV and increased by 20 mg every 2 hours until the desired diuresis is obtained. The usual IV initial dose for Bumex is 1 to 2 mg once or twice daily, but it is more often given in a continuous infusion of 10 mg over 24 hours.

The practitioner may initially use a thiazide diuretic, such as hydrochlorothiazide (HCTZ) (HydroDIURIL, Urozide ) and metolazone (Zaroxolyn), for older adults with mild volume overload. Zaroxolyn is a long-acting agent and is therefore often given every second, third, or fourth day, depending on patient need and tolerance.

Unlike loop diuretics, the action of thiazides is self-limiting (i.e., diuresis decreases after edema fluid is lost). Therefore the dehydration that may occur with loop diuretics is not common with these drugs. Patients also prefer thiazides because of the gradual onset of diuresis.

As HF progresses, many patients develop diuretic resistance with refractory edema. The health care provider may choose to manage this problem by prescribing both types of diuretics.

Monitor for and prevent potassium deficiency (hypokalemia) from diuretic therapy. The primary signs of hypokalemia are nonspecific neurologic and muscular symptoms, such as generalized weakness, depressed reflexes, and irregular heart rate. A potassium supplement may be prescribed for some patients. Other practitioners prescribe a potassium-sparing diuretic, such as spironolactone (Aldactone), for patients at risk for dysrhythmias from hypokalemia. Although not as effective as other diuretics, Aldactone helps retain potassium and thus decrease the risk of ventricular dysrhythmias.

Patients being managed with ACE inhibitors or ARBs and diuretics at the same time may not experience hypokalemia. However, if their kidneys are not functioning well, they may develop hyperkalemia (elevated serum potassium level). Review the patient’s serum creatinine level. If the creatinine is greater than 1.8 mg/dL, notify the health care provider before administering supplemental potassium.

The health care provider may prescribe venous vasodilators (e.g., nitrates) for the patient with HF who has persistent dyspnea. Significant constriction of venous and arterial blood vessels occurs to compensate for reduced CO. Constriction reduces the volume of fluid that the vascular bed can hold and increases preload. Venous vasodilators may benefit by:

• Returning venous vasculature to a more normal capacity

• Decreasing the volume of blood returning to the heart

• Improving left ventricular function

Nitrates may be administered IV, orally, or topically. IV nitrates are used most often for acute HF. These drugs cause primarily venous vasodilation but also a significant amount of arteriolar vasodilation. Monitor the patient’s blood pressure when starting nitrate therapy or increasing the dosage. Patients may initially report headache, but assure them that they will develop a tolerance to this effect and that the headache will cease or diminish. Acetaminophen (Tylenol, Exdol ) can be given to help relieve discomfort.

Unfortunately, tolerance to the vasodilating effects develops when nitrates are given around-the-clock. To prevent this tolerance, the health care provider may prescribe at least one 12-hour nitrate-free period out of every 24 hours (usually overnight). Nitrates such as isosorbide (Imdur, ISMO) are prescribed to provide nitrate-free periods and reduce the problem of tolerance. Chapter 40 discusses nitrates in more detail.

 Nclex Examination Challenge

Physiological Integrity

A client has been taking furosemide (Lasix) for the past 3 years. The hospital laboratory notifies the nurse that the client’s serum potassium level is 2.9 mEq/L. What is the nurse’s best action at this time?

A. Notify the health care provider.

B. Ask the lab to retest the potassium level.

C. Give potassium as an IV infusion.

D. Withhold this morning’s Lasix dose.

Drugs That Enhance Contractility

Contractility of the heart can also be enhanced with drug therapy. Positive inotropic drugs are most commonly used, but vasodilators and beta-adrenergic blockers may also be administered. For chronic HF, low-dose beta blockers are most commonly used. Digoxin (Lanoxin) may be prescribed to improve symptoms, thereby decreasing dyspnea and improving functional activity. This older and long-used drug is not expensive. In some settings, nesiritide (Natrecor) may be administered for end-stage HF, although this drug is very expensive (see discussion of Natrecor for acute HF on p. 751).

Digoxin

Although not as commonly used today, digoxin (Lanoxin, Novodigoxin ), a cardiac glycoside, has been demonstrated to provide symptomatic benefits for patients in chronic heart failure (HF) with sinus rhythm and atrial fibrillation. Digoxin (sometimes called “dig”) therapy reduces exacerbations of HF and hospitalizations when added to a regimen of ACE inhibitors or ARBs, beta blockers, and diuretics. However, it may increase mortality due to drug toxicity, especially in older adults.

The potential benefits of digoxin include:

• Increased contractility

• Reduced heart rate (HR)

• Slowing of conduction through the atrioventricular node

• Inhibition of sympathetic activity while enhancing parasympathetic activity

Digoxin is erratically absorbed from the GI tract. Many drugs, especially antacids, interfere with its absorption. It is eliminated primarily by renal excretion. Older patients should be maintained on lower doses of the drug than younger patients.

 Nursing Safety Priority

Drug Alert

Increased cardiac automaticity occurs with toxic digoxin levels or in the presence of hypokalemia, resulting in ectopic beats (e.g., premature ventricular contractions [PVCs]). Changes in potassium level, especially a decrease, causes patients to be more sensitive to the drug and cause toxicity.

The clinical manifestations of digoxin toxicity are often vague and nonspecific and include anorexia, fatigue, blurred vision, and changes in mental status, especially in older adults. Toxicity may cause nearly any dysrhythmia, but PVCs are most commonly noted. Assess for early signs of toxicity such as bradycardia and loss of the P wave on the ECG. Carefully monitor the apical pulse rate and heart rhythm of patients receiving digoxin.

The health care provider determines the desirable heart rate (HR) to achieve. Some health care providers prefer a rate less than 60 beats per minute. Report the development of either an irregular rhythm in a patient with a previously regular rhythm or a regular rhythm in a patient with a previously irregular one. Monitor serum digoxin and potassium levels (hypokalemia potentiates digoxin toxicity) to identify toxicity. Older adults are more likely than other patients to become toxic because of decreased renal excretion.

Any drug that increases the workload of the failing heart also increases its oxygen requirement. Be alert for the possibility that the patient may experience angina (chest pain) in response to digoxin.

Other Inotropic Drugs

Patients experiencing acute heart failure (HF) are candidates for IV drugs that increase contractility. For example, beta-adrenergic agonists, such as dobutamine (Dobutrex), are used for short-term treatment of acute episodes of HF. Dobutamine improves cardiac contractility and thus cardiac output and myocardial-systemic perfusion.

A more potent drug used for acute HF, milrinone (Primacor), functions as a vasodilator/inotropic medication with phosphodiesterase activity. Also known as a phosphodiesterase inhibitor, this drug increases cyclic adenosine monophosphate (cAMP), which enhances the entry of calcium into myocardial cells to increase contractile function. Like the beta-adrenergic agonists, Primacor is given IV.

Levosimendan (Simdax) is a calcium-sensitizing medication and a positive inotropic drug. It appears to bind to troponin C in the heart muscle and therefore increases the contraction of the heart. Simdax is used most often in patients who have had or are at high risk for myocardial infarction. Chapter 40 discusses inotropic drugs in more detail.

 Nclex Examination Challenge

Physiological Integrity

An older adult taking digoxin and furosemide (Lasix) for chronic heart failure is admitted to the emergency department (ED) with an apical pulse of 52. A family member states that the client has fallen four times this week. What is the nurse’s first action?

A. Call the ED physician immediately.

B. Draw a serum digoxin level.

C. Assess for signs of hypokalemia.

D. Establish the client’s airway.

< div class='tao-gold-member'>

Only gold members can continue reading. Log In or Register to continue

Share this:

• Click to share on Twitter (Opens in new window)
• Click to share on Facebook (Opens in new window)

Related

Related posts:

1. End-of-Life Care
2. Care of Preoperative Patients
3. Care of Patients with HIV Disease and Other Immune Deficiencies
4. Care of Patients with Noninfectious Lower Respiratory Problems

Stay updated, free articles. Join our Telegram channel

Join